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Abstract
Background: The glycosphingolipid sulfatide has previously been found in several mammalian
tissues, but information on the uptake of exogenously administered sulfatide in different organs in
vivo is limited. In pancreatic beta cells, sulfatide has been shown to be involved in insulin processing
and secretion in vitro. In this study, we examined the uptake of exogenously administered sulfatide
and its distribution to the pancreatic beta cells. This might encourage future studies of the
function(s) of sulfatide in beta cell physiology in vivo. Radioactive sulfatide was given orally to mice
whereafter the uptake of sulfatide in the gastrointestinal tract and subsequent delivery to the
pancreas was examined. Sulfatide uptake in pancreas was also studied in vivo by i.p. administration
of radioactive sulfatide in mice, and in vitro in isolated rat islets. Isolated tissue/islets were analysed
by scintillation counting, autoradiography and thin-layer chromatography-ELISA.
Results: Sulfatide was taken up in the gastrointestinal tract for degradation or further transport
to other organs. A selective uptake of short chain and/or hydroxylated sulfatide fatty acid isoforms
was observed in the small intestine. Exogenously administered sulfatide was found in pancreas after
i.p, but not after oral administration. The in vitro studies in isolated rat islets support that sulfatide,
independently of its fatty acid length, is endocytosed and metabolised by pancreatic islets.
Conclusion:  Our study supports a selective uptake and/or preservation of sulfatide in the
gastrointestinal tract after oral administration and with emphasises on pancreatic sulfatide uptake,
i.p. administration results in sulfatide at relevant location.
Background
Sulfatide (3'-sulfo-galactosylceramide) is a glycosphingol-
ipid which has previously been found in substantial
amounts in the nervous system, kidneys, gastrointestinal
tract, liver and within the insulin producing beta cells in
pancreas [1-3]. Several functions have been attributed to
sulfatide, such as interaction with proteins in the extracel-
lular milieu, involvement in bacterial-host binding, inter-
action with membrane component such as receptors and
ion channels [1] and regulation of immunological cells
[4-9]. Studies during the past decade also suggest that sul-
fatide is involved in insulin processing and regulation of
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insulin secretion in vitro [10-12] and is thus a molecule to
be considered in the context of beta cell function.
The sulfatide fatty acid isoform varies between cell types
and tissue structures. In the brain, which has a high sul-
fatide content, the major source is myelin where sulfatide
mainly contains long unsaturated and hydroxylated fatty
acids. In the pancreatic beta cells, saturated fatty acids
without hydroxylation are major isoforms. The short 16
carbon atom (C16:0) isoform comprises one and the
longer 24 carbon atom (C24:0) the other major species in
islets [10,13]. The length, saturation and hydroxylation of
the fatty acid chain is one of the factors affecting the phys-
ical/chemical properties of the molecule, and several stud-
ies suggest that the fatty acid composition of
glycosphingolipids is important for its biological func-
tion(s) [14-17]. Our results suggest that this is also the
case for pancreatic beta cells. Among the two major iso-
forms of sulfatide in beta cells, the short chain isoform,
C16:0, is responsible for insulin crystal preservation in
vitro [3].
Type 2 diabetes patients are characterised by insulin resist-
ance and impaired insulin secretion, and animal models
are commonly used for pathophysiological studies of this
disease. The beta cell related C16:0 sulfatide isoform was
found in reduced amounts in the type 2 diabetes animal
models ob/ob and db/db mice, as compared with non-
diabetic Lewis rats, BALB/c mice and human pancreatic
tissue [3]. Furthermore, intra peritoneal administration of
C16:0 sulfatide to pre-diabetic Zucker rats resulted in an
ameliorated glucose induced insulin secretion [18]. This
was associated with an increase in the pancreatic sulfatide
content, but it was not determined whether this increase
was due to an uptake of sulfatide in the beta cells. Further
support for the involvement of C16:0 sulfatide in insulin
secretion includes recent results [19], derived from patch
clamp experiments, where this specific isoform was
shown to be involved in the regulation of insulin secre-
tion as described previously [12], where a mixture of sul-
fatide isoforms was used.
In anticipation of further studies of the role of sulfatide in
beta cell physiology in vivo and its potential pharmacolog-
ical effects, it is of relevance to explore the uptake of this
molecule in pancreas and islet cells. Concerning oral
administration, there have been few studies of intestinal
digestion, uptake and further organ distribution of gly-
cosphingolipids, including sulfatide. Among these are
investigations by Nilsson et al., [20,21], more than three
decades ago, in which glycosphingolipids (i.e. cerebroside
and sphingomyelin) fed to rats were incorporated into the
small intestine. However, the majority of the sphingolip-
ids investigated were degraded within the intestine, which
has also been shown by Schmelz et al. [22], thus releasing
the backbone of ceramide and subsequently sphingoid
bases, which is rapidly taken up by the intestinal cells. Sul-
fatide has been shown to be relatively resistant to acid
hydrolysis [23,24], and therefore to have potential to be
taken up as an intact molecule in the gastrointestinal tract.
To explore the uptake of exogenously added sulfatide, the
following experiments were performed: i) uptake in the
gastrointestinal tract and further transport to pancreas was
studied by oral administration of radioactive sulfatide to
BALB/c mice, ii)  uptake of specific sulfatide isoforms
(radioactive) by the pancreas after i.p injections in the
type 2 diabetic model ob/ob mouse, iii) sulfatide uptake
and metabolism, in vitro, in isolated islets of Langerhans
prepared from Lewis rat was examined and different iso-
forms of sulfatide were compared.
Results
Uptake of 3H-sulfatide administered orally to BALB/c mice
Radioactive 3H-sulfatide taken up in the gastrointestinal
tract was determined by scintillation counting, and radio-
activity was found in isolated stomach, duodenum/jeju-
num, ileum and terminal ileum 1–6 hours after
administration (Table 1). This finding supports the idea
that sulfatide and/or its degradation products has been
taken up in these compartments. Significantly lower radi-
oactivity was found in the stomach 5–6 hours than 1–2
hours after sulfatide injection, and in the intestinal parts
24 hours as compared with 5–6 hours after administra-
tion. This indicates that sulfatide had been degraded and/
Table 1: Radioactivity measurements in lipid extracts of intestine, stomach and liver after oral administration of 3H-sulfatide
Hours after sulfatide 
load
Stomach dpm/mg 
protein
Duodenum/Jejunum 
dpm/mg protein
Ileum dpm/mg protein Terminal ileum dpm/
mg protein
Liver dpm/mg protein
1–2 6210 ± 1203 (8) 360 ± 58 (8) 1208 ± 238 (8) 2973 ± 2290 (3) 7 ± 2 (5)
5–6 522 ± 145 (7)** 222 ± 47 (7) (n.s.) 473 ± 115 (7)* 523 ± 93 (7) (n.s.) 15 ± 3 (7) (n.s.)
24 n.d. (3) 40 ± 10 (7)** 55 ± 8 (4)** 40 ± 10 (4)** n.d (3)
n.d. (3) n.d. (3)
BALB/c mice received sulfatide (250 nmol-1 μmol/mL, 1.7 × 106 dpm/mouse of 3H-sulfatide) orally, whereafter the animals were sacrificed after 1–
2 hours (n = 8), 5–6 hours (n = 7) or 24 hours (n = 7). Values are mean ± SEM (n). * p < 0.05; ** p < 0.01, where 1–2 h are compared to 5–6 h after 
sulfatide load and 5–6 h are compared to 24 h after sulfatide load. n.d. = not detected, n.s. = not significant.Lipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
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or transported to another compartment by those time
points. In the intestinal parts, approximately 1–5% of the
orally applied sulfatide was found and in the stomach the
corresponding number was 10–25% (1–2 hours after
administration).
The liver, which has a rapid lipid turnover, showed low
levels of radioactivity 1–6 hours after administration as
compared with the intestine (Table 1), and in pancreas no
radioactivity could be detected in either of the experi-
ments. In serum, 2–3 dpm/μL sera could be detected in
four out of the seven samples at 5–6 hours after sulfatide
administration, whereas the rest of the time intervals were
below detection limit. Faeces were only examined qualita-
tively, as described below, owing to the large variation of
sampling between experiments.
To verify that intact 3H-sulfatide was present in the iso-
lated intestine and stomach, selected purified sulfatide
fractions were analysed using autoradiography (1–2
hours after administration, n = 8). The presence of two
sulfatide bands in the administered sulfatide fraction (Fig.
1, lane 1, brain derived sulfatide) reflects different cera-
mide compositions, owing to a mixture of fatty acid iso-
forms. In the stomach, two corresponding bands were
seen and in similar proportions, while the intestinal parts
only contained the slower migrating radioactive sulfatide
(Figure 1). Thus, selective uptake and/or preservation of
slow migrating sulfatide fatty acid isoforms were observed
in the small intestine. Faeces specimens (n = 6), in agree-
ment with findings in the stomach, had a labeled sulfatide
composition resembling the given sulfatide (Fig. 1).
Owing to low radioactivity in samples isolated 5–6 and 24
hours after administration, analysis of sulfatide by autora-
diography was not possible.
The total sulfatide amount (endogenous pool plus exoge-
nous uptake) was measured using TLC-ELISA in the
respective tissues, and the results are summarized in Table
2. A significantly higher concentration of sulfatide was
found in the stomach, duodenum/jejunum and ileum of
animals 1–2 hours than 5–6 hours after sulfatide admin-
istration. This was also observed for the stomach and
intestinal parts when animals were compared 1–2 hours
and 24 hours after sulfatide application. These results fur-
ther support an uptake of sulfatide in the gastrointestinal
tract after oral administration, followed by fast (within 24
hours) degradation and/or removal of sulfatide, which
could result in the endogenous "steady-state" level(s).
Uptake of 3H-sulfatide isoforms administered i.p. to ob/ob 
mouse
Radioactive  3H-sulfatide isoforms (C12:0 and C16:0)
taken up by pancreas 6 or 24 hours after i.p injection were
determined using scintillation counting. In animals
injected with C12:0 sulfatide, 1202 ± 275 dpm/mg pro-
tein (n = 4) and 1520 ± 442 dpm/mg protein (n = 4) were
detected 6 and 24 hours after administration, respectively.
When C16:0 sulfatide were administered, 789 ± 135 dpm/
mg protein (n = 6) and 656 ± 93 dpm/mg protein (n = 6)
were detected 6 and 24 hours after administration, respec-
tively. There were no significant changes in radioactivity
(cpm/mg protein) when the different isoforms or the two
time periods were compared. Approximately 0.5-1% of
the radioactive labeled sulfatide isoforms given to the ani-
mals were found in pancreas after 6 and 24 hours, corre-
sponding to approximately 1 nmol sulfatide, assuming
that the sulfatide molecule was still intact.
To verify that 3H-sulfatide was present in isolated pan-
creas, saponified sulfatide fractions from pancreatic sam-
ples were analysed using autoradiography and compared
with structurally characterized sulfatide isoforms (C12:0
and C16:0 sulfatide). The results show that both C12:0
and C16:0 sulfatide isoforms are taken up by the pancreas
(Fig. 2).
The total sulfatide amount (endogenous pool plus exoge-
nous uptake) in the pancreatic tissue of ob/ob mice was
examined using TLC-ELISA. Mice receiving C16:0 sul-
3H-sulfatide uptake in the gastrointestinal tract Figure 1
3H-sulfatide uptake in the gastrointestinal tract. The 
autoradiography plate is showing the uptake of 3H-sulfatide 
(brain derived) in the gastrointestinal tract isolated from 
BALB/c mice 1–2 hours after oral sulfatide administration. 
Lipid isolation, thin-layer chromatography and autoradiogra-
phy are described under "Methods". Aliquots of the saponi-
fied "sulfatide fractions", corresponding to 2 500–3 500 dpm, 
were applied to the plate (one representative plate is 
shown). Lane 1, 3H-sulfatide; 3H-sulfatide present in, lane 2, 
stomach; lane 3, duodenum/jejunum; lane 4, ileum; lane 5, 
terminal ileum and lane 6 faeces.Lipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
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fatide showed significantly lower pancreatic sulfatide con-
centrations 24 hours after administration (54 ± 9 pmol/
mg protein, n = 6, p < 0.05) than 6 hours after sulfatide
administration (85 ± 10 pmol/mg protein, n = 6). Thus,
these results lent support to the idea of sulfatide being
degraded 24 hours after administration. Further support
for an uptake of C16:0 sulfatide in pancreas 6 hours after
i.p administration is the occurrence of a slow migrating
band on the TLC plate (Figure 3, lane 5, lower band), as
compared with sulfatide isolated from pancreas of ob/ob
mice previously reported [3] (Fig. 3, lane 7), where mainly
long-chain sulfatide isoforms were found (upper band).
Owing to the fact that the Sulph I antibody has a 5–10
fold lower affinity for C12-C14 sulfatide isoforms com-
pared with C16-C24 isoforms (unpublished data), we
were unable to obtain reliable data regarding the total
amount of sulfatide (endogenous pool plus exogenous
uptake) in the animals receiving C12:0 sulfatide.
Uptake of sulfatide isoforms in isolated rat islets
The C16:0 isoform of sulfatide was shown to be taken up
by the islets of Langerhans in vitro (Fig. 4B, Table 3, n = 4).
As early as after 6 hours of culturing, sulfatide had been
degraded to ceramide and after 24 hours of culturing,
sphingomyelin was synthesised from degraded or par-
tially degraded sulfatide (Fig. 4B). Part of the radioactivity
was found in the fraction migrating as standard galactos-
Table 2: Sulfatide in the intestine, stomach and liver after oral administration of 3H-sulfatide
Hours after sulfatide 
load
Stomach nmol/mg 
protein
Duodenum/Jejunum 
nmol/mg protein
Ileum nmol/mg 
protein
Terminal ileum nmol/
mg protein
Liver nmol/mg protein
1–2 0,58 ± 0,14 (8) 0,09 ± 0,01 (8) 0,24 ± 0,02 (8) 0,61 ± 0,26 (3) 0,004 ± 0,001 (5)
5–6 0,18 ± 0,03 (7)* 0,04 ± 0,01 (7)* 0,08 ± 0,02 (7)** 0,08 ± 0,03 (7) (n.s.) 0,004 ± 0,001 (7) (n.s)
24 0,26 ± 0,04 (3)* 0,03 ± 0,01 (7)* 0,05 ± 0,01 (7)** 0,05 ± 0,01 (7) (n.s.) 0,006 ± 0,003 (3) 
(n.s.)
BALB/c mice received sulfatide (250 nmol-1 μmol/mL, 1.7 × 106 dpm/mouse of 3H-sulfatide) orally, whereafter the animals were sacrificed after 1–
2 hours (n = 8), 5–6 hours (n = 7) or 24 hours (n = 7). Values are mean ± SEM (n). Sulfatide was quantified using TLC-ELISA.
* p < 0.05; ** p < 0.01, with respect to the sulfatide concentrations 1–2 hours after sulfatide administration. n.s. = not significant.
Sulfatide in pancreas of ob/ob mice Figure 3
Sulfatide in pancreas of ob/ob mice. Thin layer chroma-
tography of sulfatide in whole pancreas isolated from ob/ob 
mice given C16:0 sulfatide. The extraction and lipid isolation 
procedure as well as the TLC-ELISA method are described 
under "Methods". Lipids corresponding to approximately 3–4 
mg tissue protein were applied (one representative plate is 
shown). Lane 1, seminolipid (120 pmol); lane 2, sulfated lac-
tosylceramide (20 pmol); lane 3, sulfatide (40 pmol); lane 4, 
C16:0 sulfatide standard (25 pmol); lane 5, 6 hours after 
administration; lane 6, 24 hours after administration and lane 
7, sulfatide isolated from untreated ob/ob mouse.
3H-sulfatide uptake in the pancreas Figure 2
3H-sulfatide uptake in the pancreas. The autoradiogra-
phy plate is showing the uptake of 3H-C12:0 sulfatide (A) and 
3H-C16:0 sulfatide (B) in the pancreas isolated from ob/ob 
mice 6 and 24 hours after i.p. administration. Lipid isolation, 
thin-layer chromatography and autoradiography are 
described under "Methods". Aliquots of the saponified "sul-
fatide fractions", corresponding to 2 500–3 500 dpm, were 
applied to the plate (one representative plate is shown). A. 
Lane 1, 3H-C12:0 sulfatide; 3H-C12:0 sulfatide taken up by 
pancreas 6 hours (lane 2) and 24 hours (lane 3) after adminis-
tration. B. Lane 1, 3H-C16:0 sulfatide; 3H-C16:0 sulfatide 
taken up by pancreas 6 hours (lane 2) and 24 hours (lane 3) 
after administration.
A BLipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
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ylceramide after 6 and 24 hours (Table 3), probably pro-
duced by removal of the sulfate group from sulfatide.
About 0.7 ± 0.2 % (SEM, n = 7) of the 3H-C16:0 sulfatide
added to the islets was taken up after 6–24 hours, corre-
sponding to 0.4 ± 0.1 nmol (SEM, n = 7), which is consid-
ered a relatively large amount of sulfatide, since 500 Lewis
rat islets normally contains approximately 1–2 nmol sul-
fatide [2].
The C12:0 and C24:0 sulfatide isoforms were also taken
up by the rat islets, but since a lower amount of radioac-
tivity was incorporated in these sulfatide isoforms (dpm/
nmol sulfatide), as compared with C16:0 sulfatide, the
degradation products could not be visualized on the TLC-
plate (Fig. 4A and 4C, Table 3). A control experiment was
performed by applying approximately 4000 dpm of C16:0
sulfatide (similar amount as in Fig. 4A and 4C for C12:0
and C24:0, respectively) to the TLC-plate and, as expected,
the degradation products were absent (data not shown).
Approximately 0.4 ± 0.1% (SEM, n = 8) of 3H-C12:0 sul-
fatide and 1.9 ± 0.6% (SEM, n = 8) of 3H-C24:0 sulfatide
were taken up by the islets after 6–24 hours, correspond-
ing to 0.3 ± 0.1 nmol (SEM, n = 8) and 1.0 ± 0.3 nmol
(SEM, n = 8), respectively.
Discussion
This study supports the idea that sulfatide can be taken up
by pancreas when administered i.p, and in vitro studies
3H-sulfatide uptake in isolated pancreatic islets Figure 4
3H-sulfatide uptake in isolated pancreatic islets. The autoradiography plates are showing the uptake of 3H-sulfatide iso-
forms (C12:0, C16:0 and C24:0) in isolated rat islets of Langerhans. Isolation and culturing of islets, lipid isolation, thin-layer 
chromatography and autoradiography are described under "Methods". Aliquots of the saponified "sulfatide fractions", corre-
sponding to 4 000–20 000 dpm (islets cultured with C12:0 and C24:0 sulfatide) or 40 000–100 000 dpm (islets cultured with 
C16:0 sulfatide) were applied to the plates (one representative plate is shown). Lane 1, 3H-sphingomyelin, 3H-sulfatide, 3H-
galactosylceramide and 3H-ceramide standards. A. Lane 2, 3H-C12:0 sulfatide standard; uptake of 3H-C12:0 sulfatide in rat islets 
after 6 hours (lane 3) and 24 hours (lane 4). B. Lane 2, 3H-C16:0 sulfatide standard; uptake of 3H-C16:0 sulfatide in rat islets 
after 6 hours (lane 3) and 24 hours (lane 4). C. Lane 2, 3H-C24:0 sulfatide standard; uptake of 3H-C24:0 sulfatide in rat islets 
after 6 hours (lane 3) and 24 hours (lane 4).
A B
C
Table 3: Radioactivity distribution corresponding to 3H-labelled lipids isolated from rat islets cultured with 3H-sulfatide
C12:0 sulfatide C16:0 sulfatide C24:0 sulfatide
6 hours 24 hours 6 hours 24 hours 6 hours 24 hours
Lipids % dpma % dpma % dpma
Ceramide 5–8 8–12 5–8 11–20 3–5 4–10
Galactosylceramide 2–4 2–4 1 2–3 1–2 1
Sulfatide 86–89 80–84 88–93 67–81 93–95 84–93
Sphingomyelin 4 5–7 1–3 6–10 1–2 1–4
a % dpm = dpm for the individual scraped out lipid fractions/dpm applied to the HPTLC-plate, presented as intervals (n = 4).Lipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
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further show the ability of sulfatide to be endocytosed and
metabolized by pancreatic islet cells. Sulfatide can also be
taken up in the gastrointestinal tract after oral administra-
tion, which includes uptake and/or preservation of
selected fatty acid isoforms of sulfatide. However, with the
experimental conditions used in this study, oral adminis-
tration of sulfatide did not result in a distribution to the
pancreatic islet cells.
The presence of sulfatide in the gastrointestinal tract of
mammals has been reported in several studies [23,25-27]
and the amount of sulfatide exceeded those in the kid-
neys, which has a high expression of sulfatide [1]. Moreo-
ver, Natomi et al. [23,27] suggest that long-chain
hydroxylated (C22-C28) sulfatides dominate in the gas-
tric and proximal intestinal mucosa, including duodenum
and jejunum. A more recent study has also shown that the
intestinal sulfatide contains short chain hydroxylated and
non-hydroxylated C16:0 [28]. The band migration
observed on the TLC-plate corresponds to the different
sulfatide isoforms, where long chain fatty acid sulfatide
migrates as an upper band and sulfatide containing short
fatty acid chains and hydroxylated fatty acids (long and
short fatty acid chains) migrates more slowly. Interest-
ingly, our findings suggest selective uptake and/or preser-
vation of slow migrating sulfatide isoforms in the
intestine, corresponding to the endogenous sulfatide iso-
forms described above as being present in this compart-
ment. However, the present study gives no information
about the precise fatty acid composition of endocytosed
sulfatide.
Oral administration of the sphingolipid sphingomyelin
and simple glycosphingolipids as galactosylceramide/glu-
cosylceramide, has shown that these compounds undergo
very little cleavage in the stomach, but are instead hydro-
lyzed in the small intestine of mammals by alkaline
sphingomyelinase, glucosylceramidase and ceramidase
[21,22,29,30]. The sphingosine and/or ceramide derived
from this hydrolysis have been shown to be taken up by
intestinal cells and degraded to fatty acids or incorporated
in complex sphingolipids [20,22]. Similar hydrolysis,
involving arylsulphatase A activity, in the luminal com-
partment might also affect orally administered sulfatide.
However, to the best of our knowledge, arylsulphatase A
activity has not been reported to be present in this com-
partment. Sulfatide might also be desulfated by acidic
hydrolysis but has been shown to be relatively resistant to
acid hydrolysis, i.e. only 10% was hydrolysed at 0.1 M
HCl (37°C) after 24 hours [23]. The results in this study
support the idea that intact sulfatide is taken up by the
intestine for degradation in the epithelial cells or for fur-
ther distribution to other organs, such as the liver. How-
ever, the fact that less sulfatide is found in the intestinal
compartment 6–24 h hours after injection might in addi-
tion to degradation within epithelial cells be due to that
most of it has already passed thorough the intestine at
those time points. Thus, the degradation of sulfatide in
the intestine could be fast, such that the steady state level
is determined by the passage of sulfatide through the gut.
The small amount of radioactivity found in the liver frac-
tion does not exclude the possibility that there is relatively
high uptake in this compartment, since this organ has a
high lipid turnover and rapid transport of these com-
pounds.
Although our data suggest that oral administration of sul-
fatide does not result in further distribution to pancreas,
uptake of sulfatide in the intestine might still be of interest
in relation to its role in type 1 diabetes (an autoimmune
disorder) for a number of reasons: 1) Sulfatide antibodies
is present in type 1 diabetic individuals [31,32], indicating
a possible involvement in the pathogenesis 2) sulfatide
treatment delayed the onset of diabetes in BB-rats [33] 3)
treatment of NOD mice with sulfatide prevented diabetes
in these mice [34]. The mechanism remains enigmatic,
but CD1d presentation by intestinal antigen presenting
cells to functional CD1d-restricted NKT and T-cells is a
promising possibility [35-37]. Thus it was an important
finding that sulfatide could be taken up in the gastrointes-
tinal tract without being fully degraded. These results
imply that future studies on sulfatide treatments are feasi-
ble.
Since ob/ob mice selectively lack the C16:0 sulfatide iso-
form in pancreas [3], this model was used to investigate
whether this specific isoform could be taken up in pan-
creas. This experiment was performed using i.p. injec-
tions, since oral administration of sulfatide in BALB/c
mice did not show any uptake of this glycosphingolipid in
pancreas. Although a low percentage of the administered
sulfatide ended up in pancreas, the uptake resulted in a
doubling of the sulfatide concentration in pancreas 6
hours after administration as compared with previous
findings in adult ob/ob mice [3]. Thus the uptake of sul-
fatide seems to be high in relation to the endogenous
amount. The significantly lower concentration of sulfatide
in pancreas 24 hours as compared with 6 hours after
administration indicates that the C16:0 sulfatide is endo-
cytosed and thereafter partly degraded after this time
period, which is in agreement with the results from the in
vitro experiments using isolated rat islets. Thus the radio-
activity remaining in pancreas 24 hours after administra-
tion probably represents intact sulfatide plus the
degradation product(s) of this molecule.
Both non-native C12:0 sulfatide and the C16:0 isoform
were given i.p, and similar results regarding pancreatic
uptake was observed. The in vitro studies further support
the C12:0 and C16:0 isoforms being taken up by islets,Lipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
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and this was also observed with the long chain beta cell
sulfatide isoform (C24:0). The physical/chemical proper-
ties of sulfatide vary with different fatty acid length,
including their ability to be incorporated in lipid mem-
branes. In the present study, this phenomenon is evident
in the intestine, where selected isoforms were taken up,
but seem not to be the case for pancreatic islets. Thus, our
results suggest that the uptake of different sulfatide iso-
forms in islets occurs independently of the length of the
fatty acid chain, i.e. an unspecific endocytosis occurs. Sul-
fatide is further degraded within the islets and the produc-
tion of ceramide observed probably represents a
degradation product of sulfatide within the lysosomes,
which is unable to exit this compartment [38]. This find-
ing should therefore not be interpreted as increased cera-
mide synthesis resulting in induction of apoptosis [39].
Conclusion
In conclusion, i.p administration of the glycosphingolipid
sulfatide results in uptake in pancreas, which probably
represents endocytosis by pancreatic beta cells. Although
oral administration did not show pancreatic uptake, sul-
fatide was taken up in the gastrointestinal tract, where spe-
cific fatty acid isoforms of sulfatide are preserved. These
results suggest that sulfatide could be endocytosed in rel-
evant compartments for future in vivo experiments explor-
ing the role of sulfatide in beta cell function and
pathogenesis of type 2 as well as type 1 diabetes.
Methods
Animals
Lewis rats (male) were purchased from Møllegaard (L1.,
Skensved, Denmark) and BALB/c mice (male) from Bom-
holtgaard (Ry, Denmark) and bred in the stables at Bar-
tholin Instituttet, Copenhagen, Denmark. Male, C57BL/
6J-Lepob (ob/ob) mice were purchased from Bomholt-
gaard (Ry, Denmark). The principles of laboratory animal
care (NIH publication no. 85–23, revised 1985), were fol-
lowed, and the experiments were approved by the Danish
council for animal welfare under the Ministry of Justice.
Standards and antibodies
Sulfatide and galactosylceramide used as standard were
purified from pig brain according to the procedure previ-
ously described [40]. Other lipid standards were prepared
from human tissues [41]. The production and characteri-
zation of the monoclonal antibody Sulph I have been
described previously [42]. The antigens recognized are the
glycolipids sulfatide, sulfated lactosylceramide and semi-
nolipid. The alkaline phosphatase conjugated anti-mouse
IgG + IgM antibody was purchased from Jackson Labora-
tories (West Grove, PA, USA).
Semisynthesis of sulfatide with uniform fatty acids
The synthesis of sulfatide with uniform fatty acids has pre-
viously been described [18]. Briefly, lysosulfatide was pre-
pared from brain sulfatide, which comprises a mixture of
fatty acid isoforms, using alkaline hydrolysis. The acyl
chlorides of the fatty acids lauric acid (C12:0), palmitic
acid (C16:0) and lignoceric acid (C24:0) were prepared by
reaction with oxaloyl chloride. Lysosulfatide was rea-
cylated with the fatty acid chloride whereafter confirma-
tion of the sulfatide structure was performed by
electrospray ionisation-mass spectrometry (Quadrupol-
time of flight, Micromass, Manchester, UK) in the nega-
tive mode.
Radiolabelling of sulfatide
Structurally characterized sulfatide, isolated from brain or
synthesized with a uniform fatty acid, galactosylceramide
and ceramide, used as standards, was tritium labelled in
the ceramide portion with Pd(OAc)2/NaB3H4, as previ-
ously described [43].
Oral administration of 3H-sulfatide to BALB/c mice
Phosphate buffered saline (pH 7.2) was added to tubes
containing evaporated sulfatide derived from brain (mix-
ture of isoforms, 250 nmol-1 μmol/mL), including 3H-
sulfatide giving the specific activity of 15 000–70 000
dpm/nmol sulfatide, and the mixture was sonicated with
a Branson S-250 sonifier (Branson Ultrasonics Corp.,
Danbury, USA) for 2 × 20 sec at 25 W prior to use. The
concentration of 3H-sulfatide in the solution was deter-
mined by scintillation counting, and >50% was found in
solution.
Male, 8–10 weeks old BALB/c mice were divided into
three groups and given brain derived sulfatide orally (100
μL, approximately 20–50 nmol/mice, 1.7 × 106 dpm/
mouse). The animals were sacrificed (by carbon dioxide
asphyxiation) after 1–2 hours (n = 8), 5–6 hours (n = 7)
or 24 hours (n = 7). Food and water were allowed ad libi-
tum. From each animal, stomach, intestine, liver, pancreas
and blood were dissected under sterile conditions. The
intestine was divided into three parts, representing duode-
num/jejunum, ileum and terminal ileum and these three
parts were rinsed with approximately 2 mL phosphate
buffered saline after dissection. Serum was derived from
the blood samples for analysis. Tissue samples were stored
at -20°C prior to analysis.
I.p. administration of 3H-sulfatide isoforms to ob/ob mice
Phosphate buffered saline (pH 7.2) was added to tubes
containing evaporated sulfatide with a specific fatty acid
length (500 nmol/mL of C12:0 and C16:0 sulfatide),
including 3H-sulfatide of each specific isoform giving the
required specific activity of 35 000 dpm/nmol sulfatide,
and the mixture was sonicated with a Branson S-250 son-Lipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
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ifier (Branson Ultrasonics Corp.) for 2 × 20 sec at 25 W
prior to use. The recovery of 3H-sulfatide in the solution
was determined by scintillation counting and approxi-
mately 90% of C16:0 and C12:0 sulfatide were found in
solution.
Male, 8–10 weeks old, ob/ob mice (blood glucose 5–15
mM) were divided into two groups and given C12:0 or
C16:0 sulfatide i.p (300 μL, 5 × 106 dpm/mouse, 135
nmol/mouse). The animals were sacrificed (using carbon
dioxide asphyxiation) after 6 hours (C12:0, n = 4; C16:0
n = 6) or 24 hours (C12:0, n = 4; C16:0 n = 6). Food and
water were allowed ad libitum. From each animal, pan-
creas was isolated under sterile conditions and tissue sam-
ples were stored at -20°C prior to analysis.
Culturing of islets in the presence of 3H-sulfatide
Pancreas form 8–10 weeks old male Lewis rats was dis-
sected under sterile conditions and used for islet isolation.
Islets of Langerhans were obtained under sterile condi-
tions using the collagenase digestion technique described
previously [44]. About 2000 islets were obtained from 3–
4 Lewis rats. Islets were suspended in culture medium
(RPMI 1640, Gibco, Paisley, UK, containing 11.0 mM glu-
cose, 10% fetal calf serum and 1% penicillin-streptomycin
(10,000 IU/mL-10,000 μg/mL, Gibco) and with the pH
adjusted to 7.35) and incubated for 20 hours in an atmos-
phere of 95% air-5% CO2 at 37°C before addition of sul-
fatide into the culture medium.
Evaporated sulfatide was resolved in fresh culture
medium (RPMI 1640, Gibco) by sonication (Branson S-
250 sonifier, Branson Ultrasonics Corp.) for 2 × 20 sec at
25 W prior to use. The recovery of 3H-sulfatide in the solu-
tion was determined by scintillation counting and
approximately 80–90% of the C12:0, C16:0 and C24:0
sulfatide isoforms were found in the culture medium. The
concentration was found to be approximately 12–15
nmol sulfatide/mL culture medium of the respective iso-
form, including 3H-C12:0 sulfatide, 3H-C16:0 sulfatide
and 3H-C24:0 sulfatide giving the required specific activity
of 50 000, 1.2 × 106 and 12 500 dpm/nmol sulfatide,
respectively.
Islets were divided into 500 islets/culture dish, put into
culturing media (as described above) containing the sep-
arate sulfatide isoforms and cultured for 6 hours (n = 4)
or 24 hours (n = 4) in an atmosphere of 95% air-5% CO2
at 37°C. During this period of culturing, heat inactivated
fetal calf serum was used (56°C for 45 minutes). Islets
were harvested and washed in phosphate buffered saline
by centrifugation and stored at -20°C prior to analysis.
Analysis of sulfatide from tissue/islets
Lipids were extracted from homogenates of tissues/islets,
after protein determination (BCA Protein Assay Reagent
method, Pierce, Rockford, USA), by adding methanol and
chloroform to give a final ratio of chloroform/methanol/
water (C/M/W, 4:8:3, by vol.) [45]. An aliquot of the lipid
homogenates was mixed with 10 mL scintillation liquid
(Ultima Gold, Packard BioScience, Groningen, The Neth-
erlands) and analysed using scintillation counting (Tri-
Carb 1500, Packard) to determine the specific radioactiv-
ity of 3H-sulfatide taken up by the tissue. Approximately
50 μL of the serum samples were analysed by scintillation
counting. Further purification was performed by silica gel-
60 chromatography (Merck, Darmstadt, Germany), as
previously described [10], where sulfatide, phospholip-
ids, sphingomyelin and ceramide were eluted with C/M/
W (65:25:4, by vol.) and gangliosides with C/M/W
(30:60:20, by vol.) The "sulfatide fraction" was saponified
in methanol:1 M KOH (1:1 v/v) [3] before autoradiogra-
phy or quantification using thin-layer chromatography-
enzyme linked immuno-sorbent assay (TLC-ELISA), as
described below.
Autoradiography
Aliquots of the saponified "sulfatide fractions", corre-
sponding to 2 500–3 500 dpm (tissue), 3 500–8 500 dpm
(islets cultured with C12:0 and C24:0 sulfatide) or 35
000–100 000 dpm (islets cultured with C16:0 sulfatide)
were applied as 8 mm bands to alumina-backed high per-
formance-TLC plates (Merck) and chromatographed in C/
M/W (65:25:4, by vol.). The plate was air dried, sprayed
with Enhance spray (NEN™ Life Science Products, Zaven-
tem, Belgium) and exposed to x-ray film for 7–14 days.
The individual sulfatide bands after chromatography were
identified by comparing with the migration of structurally
identified sulfatide standard(s). Autoradiography per-
formed on the "sulfatide fraction" purified from islets also
included structurally identified standards of galactosylce-
ramide, sphingomyelin and ceramide. In this experiment,
liquid scintillation counting, as described above, was per-
formed on samples after saponification and on scraped
out fractions of the individual lipid bands after chroma-
tography.
Quantitative determination of sulfatide by TLC-ELISA
Sulfatide was identified and quantified using a TLC-ELISA
method previously described [46] using the Sulph I anti-
body [42]. Briefly, purified standards of sulfatide and aliq-
uots of the "sulfatide fraction" were applied as 5 mm lanes
to TLC plates (10 × 20 plastic-backed, Merck) and chro-
matographed in C/M/W (65:25:4, by vol.). Plates were
sequentially incubated with the monoclonal Sulph I anti-
body, alkaline-phosphatase-conjugated anti-mouse anti-
body and 5'-bromo-4'chloro-3'indolylphosphate. All
steps were performed at room temperature. The intensityLipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
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of the developed color was determined by densitometric
scanning at 620 nm.
Statistics
The sulfatide content and/or uptake in tissues and islets
were presented as mean values ± SEM. The significance of
difference was evaluated by using Student's t-test (signifi-
cance level set at < 0.05).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MB carried out part of the lipid analyses and collected the
data, participated in the design of the experiments and
drafted the manuscript. TO carried out the administration
of sulfatide to mice. J-E M and KB participated in interpre-
tation of data and were involved in revising the manu-
script critically. PF made substantial contribution to the
design of the study, interpretation of data and in revising
the manuscript critically. All authors read and approved
the final manuscript.
Acknowledgements
We would like to acknowledge our gratitude to Britt-Marie Rynmark and 
Elzbieta Christiansen for technical assistance and Dr. David Funda for help-
ing administer sulfatide orally to mice. This work was supported by grants 
from the Swedish Medical Research Council (K2002-03X-09909-11A), "A+ 
Science Invest" and the program "Glycoconjugates in Biological Systems", 
sponsored by the Swedish Foundation for Strategic Research.
References
1. Ishizuka I: Chemistry and functional distribution of sulfoglycol-
ipids.  Prog Lipid Res 1997, 36:245-319.
2. Buschard K, Josefsen K, Horn T, Larsen S, Fredman P: Sulphatide
antigen in islets of Langerhans and in diabetic glomeruli, and
anti-sulphatide antibodies in type 1 diabetes mellitus.  APMIS
1993, 101:963-970.
3. Blomqvist M, Osterbye T, Månsson JE, Horn T, Buschard K, Fredman
P: Selective lack of the C16:0 fatty acid isoform of sulfatide in
pancreas of type II diabetic animal models.  APMIS 2003,
111:867-877.
4. Buschard K, Schloot NC, Kaas A, Bock T, Horn T, Fredman P, Roep
BO: Inhibition of insulin-specific autoreactive T-cells by sul-
phatide which is variably expressed in beta cells.  Diabetologia
1999, 42:1212-1218.
5. Ding Z, Kawashima H, Miyasaka M: Sulfatide binding and activa-
tion of leukocytes through an L-selectin- independent path-
way.  J Leukoc Biol 2000, 68:65-72.
6. Frier Bovin L, Fredman P, Månsson JE, Buschard K, Bendtzen K: In
vitro production of cytokines is influenced by sulfatide and its
precursor galactosylceramide.  FEBS Lett 1999, 455:339-343.
7. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V: Pre-
vention of autoimmunity by targeting a distinct, noninvari-
ant CD1d-reactive T cell population reactive to sulfatide.  J
Exp Med 2004, 199:947-957.
8. Roeske-Nielsen A, Fredman P, Mansson JE, Bendtzen K, Buschard K:
Beta-galactosylceramide increases and sulfatide decreases
cytokine and chemokine production in whole blood cells.
Immunol Lett 2004, 91:205-211.
9. Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G:
Presentation of the same glycolipid by different CD1 mole-
cules.  J Exp Med 2002, 195:1013-1021.
10. Fredman P, Månsson JE, Rynmark BM, Josefsen K, Ekblond A, Halldner
L, Osterbye T, Horn T, Buschard K: The glycosphingolipid sul-
fatide in the islets of Langerhans in rat pancreas is processed
through recycling; possible involvement in insulin trafficking.
Glycobiology 2000, 10:39-50.
11. Osterbye T, Jorgensen KH, Fredman P, Tranum-Jensen J, Kaas A,
Brange J, Whittingham JL, Buschard K: Sulfatide promotes the
folding of proinsulin, preserves insulin crystals, and mediates
its monomerization.  Glycobiology 2001, 11:473-479.
12. Buschard K, Hoy M, Bokvist K, Olsen HL, Madsbad S, Fredman P,
Gromada J: Sulfatide controls insulin secretion by modulation
of ATP-sensitive K+-channel activity and Ca2+-dependent
exocytosis in rat pancreatic beta-cells.  Diabetes 2002,
51:2514-2521.
13. Hsu FF, Bohrer A, Turk J: Electrospray ionization tandem mass
spectrometric analysis of sulfatide. Determination of frag-
mentation patterns and characterization of molecular spe-
cies expressed in brain and in pancreatic islets.  Biochim Biophys
Acta 1998, 1392:202-216.
14. Kannagi R, Nudelman E, Hakomori S: Possible role of ceramide in
defining structure and function of membrane glycolipids.
Proc Natl Acad Sci U S A 1982, 79:3470-3474.
15. Kannagi R, Stroup R, Cochran NA, Urdal DL, Young WW Jr., Hako-
mori S: Factors affecting expression of glycolipid tumor anti-
gens: influence of ceramide composition and coexisting
glycolipid on the antigenicity of gangliotriaosylceramide in
murine lymphoma cells.  Cancer Res 1983, 43:4997-5005.
16. Lingwood CA: Aglycone modulation of glycolipid receptor
function.  Glycoconj J 1996, 13:495-503.
17. Mamelak D, Mylvaganam M, Whetstone H, Hartmann E, Lennarz W,
Wyrick PB, Raulston J, Han H, Hoffman P, Lingwood CA: Hsp70s
contain a specific sulfogalactolipid binding site. Differential
aglycone influence on sulfogalactosyl ceramide binding by
recombinant prokaryotic and eukaryotic hsp70 family mem-
bers.  Biochemistry 2001, 40:3572-3582.
18. Blomqvist M, Carrier M, Andrews T, Pettersson K, Månsson JE, Ryn-
mark BM, Fredman P, Buschard K: In vivo administration of the
C16:0 fatty acid isoform of sulfatide increases pancreatic sul-
fatide and enhances glucose stimulated insulin secretion in
Zucker fatty (fa/fa) rats.  Diabetes Metab Res Rev 2005,
21:158-166.
19. Buschard K, Blomqvist M, Månsson JE, Fredman P, Juhl K, Gromada J:
C16:0 sulfatide inhibits insulin secretion in rat beta cells by
reducing ATP-sensitive K+ channels to ATP inhibition.  Dia-
betes 2006, 55(10):2826-2834.
20. Nilsson A: Metabolism of sphingomyelin in the intestinal tract
of the rat.  Biochim Biophys Acta 1968, 164:575-584.
21. Nilsson A: Metabolism of cerebroside in the intestinal tract of
the rat.  Biochim Biophys Acta 1969, 187:113-121.
22. Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill AH Jr.:
Uptake and metabolism of sphingolipids in isolated intestinal
loops of mice.  J Nutr 1994, 124:702-712.
23. Natomi H, Sugano K, Iwamori M, Takaku F, Nagai Y: Region-specific
distribution of glycosphingolipids in the rabbit gastrointesti-
nal tract: preferential enrichment of sulfoglycolipids in the
mucosal regions exposed to acid.  Biochim Biophys Acta 1988,
961:213-222.
24. Iwamori M, Suzuki H, Ito N, Iwamori Y, Hanaoka K: Lipid composi-
tions of human gastric fluid and epithelium: the role of sul-
fated lipids in gastric cytoprotection.  J Clin Gastroenterol 2005,
39:129-133.
25. Breimer ME, Hansson GC, Karlsson KA, Leffler H: The preparative
separation of sialic acid-containing lipids from sulphate
group-containing glycolipids from small intestine of different
animals. Analysis by thin-layer chromatography and detec-
tion of novel species.  J Biochem (Tokyo) 1983, 93:1473-1485.
26. Natomi H, Sugano K, Takaku F, Iwamori M: Glycosphingolipid
composition of the gastric mucosa. A role of sulfatides in gas-
trointestinal mucosal defense?  J Clin Gastroenterol 1990, 12
Suppl 1:S52-7.
27. Natomi H, Saitoh T, Sugano K, Iwamori M, Fukayama M, Nagai Y: Sys-
tematic analysis of glycosphingolipids in the human gastroin-
testinal tract: enrichment of sulfatides with hydroxylated
longer-chain fatty acids in the gastric and duodenal mucosa.
Lipids 1993, 28:737-742.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2006, 5:26 http://www.lipidworld.com/content/5/1/26
Page 10 of 10
(page number not for citation purposes)
28. Beausoleil HE, Lepine F, Dubreuil JD: LC-MS analysis of pig intes-
tine sulfatides: interaction with Escherichia coli STb entero-
toxin and characterization of molecular species present.
FEMS Microbiol Lett 2002, 209:183-188.
29. Nilsson A: The presence of spingomyelin- and ceramide-
cleaving enzymes in the small intestinal tract.  Biochim Biophys
Acta 1969, 176:339-347.
30. Nilsson A, Duan RD: Alkaline sphingomyelinases and cerami-
dases of the gastrointestinal tract.  Chem Phys Lipids 1999,
102:97-105.
31. Buschard K, Josefsen K, Horn T, Fredman P: Sulphatide and sul-
phatide antibodies in insulin-dependent diabetes mellitus.
Lancet 1993, 342:840.
32. Andersson K, Buschard K, Fredman P, Kaas A, Lidström AL, Madsbad
S, Mortensen H, Månsson JE: Patients with insulin-dependent
diabetes but not those with non-insulin-dependent diabetes
have anti-sulfatide antibodies as determined with a new
ELISA assay.  Autoimmunity 2002, 35:463-468.
33. Buschard K, Hageman I, Hansen AK, Fredman P: Neonatal treat-
ment of BB rats with sulphatide delays development of dia-
betes but does not change incidence.  APMIS 1995, 103:193-196.
34. Buschard K, Hanspers K, Fredman P, Reich EP: Treatment with
sulfatide or its precursor, galactosylceramide, prevents dia-
betes in NOD mice.  Autoimmunity 2001, 34:9-17.
35. Bleicher PA, Balk SP, Hagen SJ, Blumberg RS, Flotte TJ, Terhorst C:
Expression of murine CD1 on gastrointestinal epithelium.
Science 1990, 250:679-682.
36. Blumberg RS, Terhorst C, Bleicher P, McDermott FV, Allan CH,
Landau SB, Trier JS, Balk SP: Expression of a nonpolymorphic
MHC class I-like molecule, CD1D, by human intestinal epi-
thelial cells.  J Immunol 1991, 147:2518-2524.
37. van de Wal Y, Corazza N, Allez M, Mayer LF, Iijima H, Ryan M, Corn-
wall S, Kaiserlian D, Hershberg R, Koezuka Y, Colgan SP, Blumberg
RS: Delineation of a CD1d-restricted antigen presentation
pathway associated with human and mouse intestinal epithe-
lial cells.  Gastroenterology 2003, 124:1420-1431.
38. Chatelut M, Leruth M, Harzer K, Dagan A, Marchesini S, Gatt S, Sal-
vayre R, Courtoy P, Levade T: Natural ceramide is unable to
escape the lysosome, in contrast to a fluorescent analogue.
FEBS Lett 1998, 426:102-106.
39. Perry DK, Hannun YA: The role of ceramide in cell signaling.
Biochim Biophys Acta 1998, 1436:233-243.
40. Rosengren B, Fredman P, Månsson JE, Svennerholm L: Lysosulfatide
(galactosylsphingosine-3-O-sulfate) from metachromatic
leukodystrophy and normal human brain.  J Neurochem 1989,
52:1035-1041.
41. Svennerholm L, Håkansson G, Månsson JE, Vanier MT: The assay of
sphingolipid hydrolases in white blood cells with labelled nat-
ural substrates.  Clin Chim Acta 1979, 92:53-64.
42. Fredman P, Mattsson L, Andersson K, Davidsson P, Ishizuka I, Jeans-
son S, Månsson JE, Svennerholm L: Characterization of the bind-
ing epitope of a monoclonal antibody to sulphatide.  Biochem
J 1988, 251:17-22.
43. Schwarzmann G: A simple and novel method for tritium labe-
ling of gangliosides and other sphingolipids.  Biochim Biophys
Acta 1978, 529:106-114.
44. Buschard K, Aaen K, Horn T, Van Damme J, Bendtzen K: Interleukin
6: a functional and structural in vitro modulator of beta- cells
from islets of Langerhans.  Autoimmunity 1990, 5:185-194.
45. Svennerholm L, Fredman P: A procedure for the quantitative
isolation of brain gangliosides.  Biochim Biophys Acta 1980,
617:97-109.
46. Davidsson P, Fredman P, Månsson JE, Svennerholm L: Determina-
tion of gangliosides and sulfatide in human cerebrospinal
fluid with a microimmunoaffinity technique.  Clin Chim Acta
1991, 197:105-115.